Aktuella utlysningar, vecka 21, 2018

Publicerat 2018-05-23 10:14. Uppdaterat 2018-05-23 13:45

Grants Office tipsar om aktuella utlysningar

Svenska och nordiska utlysningar

Call for project funding SFO-V 2018/19

Strategiska forskningsområdet vårdvetenskap (SFO-V) utlyser upp till 10 projektbidrag om 250 000 kr för 2018 med möjlighet till ytterligare 250 000 kr för 2019. 

Closing date: 20 augusti 2018 kl 15:00. 

Call for project funding SFO-V 2018/19

BCPT Nordic Prize in basic and clinical pharmacology and toxicology

The prize is given to an eminent scientist in either of the fields of basic and/or clinical pharmacology or toxicology in honour of a life-long effort to develop and promote either or both of the disciplines in a Nordic country as well as internationally. The prize is given in honour of work that has been carried out at a public or private research institution in a Nordic country, but the recipient may as well have been born or have received his/her undergraduate training out-side this part of the world.

Eligible candidates are active researchers who have carried out basic or clinical research in the fields of pharmacology and toxicology at a high international level. The prize is either given in honour of a single major discovery or a longstanding research effort also recognized outside the Nordic region.

The prize is for personal use and is worth 10,000 €.

Closing date: 1 Aug 2018

BCPT Nordic Prize in basic and clinical pharmacology and toxicology

Forskningsanslag - Kronprinsessan Margaretas Arbetsnämnd för synskadade

Främjar medicinsk forskning rörande synskador. 

Closing date: 31 Aug 18

Forskningsanslag - Kronprinsessan Margaretas Arbetsnämnd för synskadade  

Forskningsmedel - Kungliga Vetenskapsakademien/Torsten Amundsons fond

Stöder studier om homosexualitet, dess uppkomst och förklaring, och upplysningsarbete för hävande av fördomar och oriktiga uppfattningar. Den totala budgeten är SEK 600,000. Bidrag över SEK 100,000 beviljas endast i undantagsfall. 

Closing date: 31 Aug 18

Forskningsmedel - Kungliga Vetenskapsakademien/Torsten Amundsons fond 

Anslag för klinisk cancerforskning - Radiumhemmets Forskningsfonder

Stöder projekt inom klinisk cancerforskning, där prioritet ges till patientnära forskning som företrädesvis genomförs inom Stockholms Läns Landsting och bidrar till utveckling av individualiserad cancerbehandling. Bidrag kan täcka driftkostnader, lön och apparaturkostnader. 

Closing date: 1 Sep 18

Anslag för klinisk cancerforskning - Radiumhemmets Forskningsfonder 

Projektanslag för patientnära forskning - Capio AB

Syftar till fördjupad kunskap om hur vårdinsatser kan minska patientens lidande eller öka livskvaliteten. Stöd kan ges i högst tre år.

Closing date: 3 Sep 18

Projektanslag för patientnära forskning - Capio AB 

Nordic call on personalised medicine - NordForsk

Supports Nordic projects that contribute to implementation of personalised medicine in health care. The expected funding available per project is between €1 million and €3m over up to four years.

Closing date: 4 Sep 18

Nordic call on personalised medicine - NordForsk 

Strategic mobility – Swedish Foundation for Strategic Research | Stiftelsen för Strategisk Forskning

Aims to increase personal mobility and cross-fertilisation between academia and industry. The total budget for this call is SEK 15 million. Individual grants are worth up to SEK 1.5m including overheads, of which no more than SEK 100,000 for other costs.

Closing date: 6 Sep 18 

Strategic mobility – Swedish Foundation for Strategic Research | Stiftelsen för Strategisk Forskning 

Europeiska utlysningar

JPIAMR 2018 CALL FOR NETWORKS

The intent of this call is to form Networks of motivated groups to conceptualize and develop the JPIAMR-VRI. The Networks should identify research community needs, develop catalytic ideas and strategic plans to help bring the JPIAMR-VRI to Life!

Up to 21 Networks will be funded with up to 50,000 € each to connect experts from research performing organizations, institutes, centers and infrastructures and establish expertise clusters in the AMR community.

Closing date: 4 July 2018

JPIAMR 2018 CALL FOR NETWORKS

Ferring innovation grants - Ferring Pharmaceuticals

Ferring Pharmaceuticals invites applications for its innovation grants. These support research designed to identify and validate new molecular targets in reproductive medicine and women’s health, gastroenterology and hepatology, and urology, as well as biomarker disovery.

Closing date: 11 June 2018

Ferring innovation grants - Ferring Pharmaceuticals 

Horizon prize for social innovation in Europe – improved mobility for older people - Horizon 2020

Horizon prize for social innovation in Europe – improved mobility for older people. This aims to develop innovative and sustainable mobility solutions for older people, allowing them to maintain independence and actively participate in social life. Solutions should address both technical issues linked to for example infrastructure, vehicles, software and apps and issues such as communication and integrated personalised services.

Closing date: 28 Feb 2019

Horizon prize for social innovation in Europe – improved mobility for older people - Horizon 2020 

Novel disease mechanisms for AstraZeneca preclinical compounds - AstraZeneca

AstraZeneca invites applications for its novel disease mechanisms for AstraZeneca preclinical compounds funding opportunity. This supports proposals that probe novel mechanisms for a subset of human disease, respiratory, cardiovascular, renal, and diabetes.

Closing date: 1 Aug 2018

Novel disease mechanisms for AstraZeneca preclinical compounds - AstraZeneca

Amerikanska utlysningar

Federal Funding agencies

Clinical, behavioural and physiological research testing current and novel closed loop systems (R01 clinical trial required): NIH

This Funding Opportunity Announcement (FOA) encourages applications proposing clinical trials to test a highly reliable, wearable/implantable, portable, and easy to operate system linking continuous glucose monitoring and pancreatic hormone delivery in a closed loop system.  This research is also intended to study behavioral and physiological aspects of relevance to the use and adoption of these systems. The main goal of this FOA is to improve glucose control and quality of life of patients with type 1 diabetes. Only human studies will be considered responsive to this FOA, applications involving animal or in vitro studies are not responsive to this FOA.

Closing date: November 6, 2018 (Letter of Intent), December 6, 2018, by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): RFA-DK-17-023

Clinical, behavioural and physiological research testing current and novel closed loop systems (R01 clinical trial required): NIH 

Impact of the Use of Glucose Monitoring and Control Technologies on Health Outcomes and Quality of Life in Older Adults with Type 1 Diabetes (T1D) (R01 Clinical Trial Required): NIH

This Funding Opportunity Announcement (FOA) encourages applications from proposing clinical studies of the use of current and emerging technologies for monitoring of blood glucose and insulin administration in older adults (aged 65 years or older). Older adults may have increased vulnerability to hypoglycemia, cognitive impairment and/or multiple co-morbidities which may affect the risks and benefits of these technologies in this population.  This research is intended to improve health, glucose control and quality of life of older patients with type 1 diabetes. Only human studies will be considered responsive to this FOA; applications involving animal or in vitro studies are not responsive to this FOA.

Closing date: November 6, 2018 (Letter of Intent), December 6, 2018, by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): RFA-DK-17-024

Impact of the Use of Glucose Monitoring and Control Technologies on Health Outcomes and Quality of Life in Older Adults with Type 1 Diabetes (T1D) (R01 Clinical Trial Required): NIH 

Mechanisms Underlying the Contribution of Type 1 Diabetes Disease-associated Variants (R01 Clinical Trial Not Allowed): NIH

This Funding Opportunity Announcement (FOA) encourages applications from integrative teams and individual investigators for projects to determine the mechanisms underlying the contribution of risk-associated genes and their variants for Type 1 Diabetes (T1D). See FOA for further information. The purpose is to accelerate the discovery of function of the causal genes and variants that influence the risk for disease.

Closing date: 30 days prior to the application due date (Letter of Intent), December 6, 2018, by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): RFA-DK-18-005

Mechanisms Underlying the Contribution of Type 1 Diabetes Disease-associated Variants (R01 Clinical Trial Not Allowed): NIH

Foundations

Oxalosis and Hyperoxaluria Foundation, US

The Oxalosis and Hyperoxaluria Foundation invites applications for its research grants. These support research that will lead to new diagnostics, treatments and a cure for primary hyperoxaluria and related hyperoxaluria conditions.

Applicant Eligibility: Applicants must hold a MD, PhD or equivalent by the start of the funding period and have an appointment at an academic institution.

Closing date: November 1st 2018 by 12 midnight EST

Oxalosis and Hyperoxaluria Foundation, US 

Standard awards in national glaucoma research BrightFocus Foundation, US

The BrightFocus Foundation invites applications for its standard awards in national glaucoma research. These support researchers who have already generated preliminary data, but still require significant progress before they can apply to governmental or industrial funding agencies.

Closing date: 11:59 p.m. EST (Washington, D.C.) on the day of the deadline.

Standard awards in national glaucoma research BrightFocus Foundation, US 

Länkar